Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87

LINGYU HAN¹²*, BO YUAN¹*, RYOTA SHIMADA¹, HIDEKI HAYASHI¹, NAN SI², HAI-YU ZHAO², BAOLIN BIAN² and NORIO TAKAGI¹

¹Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo 192-0392, Japan; ²Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China

Received March 8, 2018; Accepted July 18, 2018
DOI: 10.3892/ijo.2018.4567

Abstract. Glioblastoma is the most common and lethal intracranial tumor type, characterized by high angiogenic and infiltrative capacities. To provide a novel insight into therapeutic strategies against glioblastoma, the cytotoxicity of arenobufagin and hellebrigenin was investigated in the human glioblastoma cell line, U-87. Similar dose-dependent cytotoxicity was observed in the cells, whereas no detectable toxicity was confirmed in mouse primary astrocytes. Treatment with each drug downregulated the expression levels of Cdc25C, Cyclin B1 and survivin, which occurred in parallel with G2/M phase arrest. Necrotic-like cell death was only observed in the cells treated with a relatively high concentration (>100 ng/ml). These results indicate that the two drugs exhibited distinct cytotoxicity against cancerous glial cells with high potency and selectivity, suggesting that growth inhibition associated with G2/M phase arrest and/or necrosis were attributed to their toxicities. Activation of the p38 mitogen activated protein kinase (MAPK) signaling pathway was also observed in treated cells. Notably, a specific inhibitor of p38 MAPK, SB203580, itself caused a significant decrease in cell viability, and further enhanced the cytotoxicity of the two drugs, suggesting an important pro-survival role for p38 MAPK. Given that p38 MAPK serves an essential role in promoting glioblastoma cell survival, developing a novel combination regimen of arenobufagin/hellebrigenin plus a p38 MAPK inhibitor may improve the efficacy of the two drugs, and may provide more therapeutic benefits to patients with glioblastoma. The qualitative assessment demonstrated the existence of arenobufagin in the cerebrospinal fluid of arenobufagin-treated rats, supporting its clinical application.

Introduction

Glioblastoma, classified as a grade IV astrocytoma according to the World Health Organization prognostic system, is the most common and lethal type of intracranial tumor, characterized by high angiogenic and infiltrative capacities (1,2). The current standard treatment for glioblastoma consists of maximal surgical resection, radiotherapy, and concomitant and adjuvant chemotherapy with temozolomide (1,3). Despite advances in the understanding of the molecular pathogenesis of glioblastoma, diagnosis, and more promising and tailored therapeutic approaches, the median survival time of patients with glioblastoma remains <1 year (4,5). The requirement for novel therapeutic strategies remains paramount given the sustained development of drug resistance and tumor recurrence.

Bufadienolides are the major effective constituents of cino-bufacini (also known as Huachansu), a well-known Chinese medicine that comes from the dried skin of Bufo bufo gargari-zans Cantor, and cinobufacini has been used to treat patients with various types of cancer, including hepatoma, gallbladder carcinoma and lung cancer in China (6-8). The authors of the present study recently demonstrated that active bufadienolide compounds, including gamabufotalin and arenobufagin, exhibit selective cytocidal effects against intractable cancer cells, including in glioblastoma, but minimal effects on normal peripheral blood mononuclear cells (PBMCs) prepared from healthy volunteers (9). Notably, it was demonstrated that nearly non-toxic gamabufotalin concentrations on PBMCs efficiently downregulated the percentages of CD4⁺CD25⁺Foxp3⁺ regulatory T (Treg) cells (9), which have been considered to serve an important role in limiting antitumor immune response in the body and promoting immunological ignorance of cancer cells (10-12). These results suggest that bufadienolides, including gamabufotalin and arenobufagin, may provide a therapeutic benefit to patients with glioblastoma via their...
cytotoxic effects against tumor cells and antitumor immunity-promoting characteristics. Despite the selective cytotoxic effects of bufadienolides against glioblastoma and their possibility for further clinical applications, the detailed molecular mechanisms of action of these active bufadienolides in glioblastoma cells remain unexplored.

Cell cycle arrest, necrosis and apoptosis are considered the major mechanisms underlying the cytotoxic effects of the majority of chemotherapeutic drugs (13-15). A number of previous studies have demonstrated that active bufadienolides, including bufalin, arenobufagin and hellebrigenin, induce cytotoxicity associated with cell cycle arrest (16-18). They have also been implicated in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT serine/threonine kinase (Akt) signaling pathway, and downregulation of essential regulators of the cell cycle transition, such as Cdc25C and Cyclin B1, in human hepatocellular carcinoma cells (16-18). Survivin, a well-known cancer-associated protein that is highly expressed in the majority of human tumor cells, has been associated with an increase in the malignant potential of human glioma, and is considered to serve an important role in mediating radiation resistance in primary glioblastoma cells (19). In addition, members of the mitogen-activated protein kinase (MAPK) family are involved in cell cycle arrest, cell death signaling and the regulation of growth. The MAPKs include p38 kinase, c-Jun NH2-terminal protein kinase (JNK) and extracellular signal-regulated kinase (Erk) (20). Similar to Akt, Erk is usually referred to as a survival mediator involved in cytoprotection (21,22). Although p38 MAPK and JNK are generally considered to be required for the induction of cell death by diverse stimuli (21,23,24), a novel prosurvival role for p38 MAPK has been reported in human cancer cells, including in glioblastoma cells (25-27). However, whether and how these molecules contribute to the potential cytotoxic effects induced by active bufadienolides against glioblastoma cells, and the association between these molecules and cellular responses, including cell cycle arrest, remain to be elucidated.

In the current study, the cytotoxicity of two active bufadienolide compounds, arenobufagin and hellebrigenin, was investigated in the human glioblastoma cell line U-87 by focusing on proliferation inhibition associated with cell cycle arrest, necrosis as well as apoptosis, in order to provide novel insight into therapeutic approaches against glioblastoma. Primary mouse astrocytes were also used to evaluate whether the two drugs exhibited cytotoxic selectivity for cancer cells, rather than normal cells. Key regulatory molecules involved in the cell cycle and cell death were investigated to further elucidate the cytotoxic mechanisms. Considering the controversial role of p38 MAPK in cell death/survival in human cancer cells, the details of whether and how p38 MAPK is implicated in active bufadienolides-mediated cytotoxic effects in U-87 cells were also investigated using its specific inhibitor, SB203580.

Materials and methods

Materials. Arenobufagin was purchased from Baoji Herbest Bio-Tech Co., Ltd. (Baoji, China). XTT, propidium iodide (PI), proteinase K, Hoechst 33258 and ribonuclease A (RNaseA) were purchased from Merck KGaA (Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM), phenazine methosulfate, agarose X and 25% glutaraldehyde solution were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Crystal violet (C.I. 42555) Certitain<sup>a</sup> was purchased from Merck KGaA. SB203580, a specific inhibitor of p38 MAPK, and its negative control SB202474 were purchased from Merck KGaA. Fetal bovine serum (FBS) was obtained from Nichirei Biosciences, Inc. (Tokyo, Japan). High performance liquid chromatography (HPLC)-grade acetonitrile and methanol were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Mass spectrometry (MS)-grade formic acid was obtained from ROE Scientific, Inc. (Newark, DE, USA).

Isolation and identification of hellebrigenin from the dried skin of Bufo bufo gargarizans Cantor. Dried skin of Bufo bufo gargarizans Cantor was purchased from Anhui Jinchan Biochemistry Co., Ltd. (Huaibei, China), and further identified by Professor Hongjie Wang (Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China). The dried toad skin (10 kg) was cut into pieces, and then extracted under reflux with 95% ethanol into 20 liters. The extracting solution was dried with rotary evaporation at 45°C under reduced pressure (vacuum drying) to yield ~150 g residue. Following separation through a silica gel (2,000 g; 160-200 mesh; Qingdao Haiyang Chemical Co., Ltd., Qingdao, China) column chromatography with chloroform-methanol solution (50:1-1:1) with gradient elution, a total of eight fractions were obtained (Fr. 1-8). Fr. 4 (8 g) was further separated by C18 (320 ml; SP-120-50-ODS-RPS; DAISO Co., Ltd., Osaka, Japan) column chromatography using 30% (500 ml, Fr. 4.1-4.5), 40% (500 ml, Fr. 4.6-4.10), 50% (500 ml, Fr. 4.11-4.15) and 60% (400 ml, Fr. 4.16-4.19) methanol. Hellebrigenin was purified from Fr. 4.10-4.16 by preparative HPLC. It was obtained as a white powder with molecular formula of C<sub>32</sub>H<sub>32</sub>O<sub>7</sub> based on high-resolution electrospray ionization MS (HR-ESI-MS). The compound was identified as hellebrigenin with >96% purity according to previously reported values (28).

Cell culture and treatment. U-87, a human glioblastoma cell line, was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM supplemented with 10% heat-inactivated FBS, 100 U/ml of penicillin and 100 µg/ml of streptomycin (both from Wako Pure Chemical Industries, Ltd.) in a humidified atmosphere with 5% CO<sub>2</sub> at 37°C. Primary mouse glial cells were prepared according to a method previously reported with modifications (29). Briefly, the cerebral cortex of 4-5 newborn C57BL/6J mice [2-4 days old (sex unconfirmed), body weight 2-3 g, housed at 23±1°C in a room with a constant humidity of 55±5% and a regular 12-h light/12-h dark cycle together with dams] was removed and digested by trituration in PBS (Wako Pure Chemical Industries, Inc.) containing 0.25% trypsin. Dissociated glial cells were cultured in 75 cm<sup>2</sup> flasks (BD Biosciences, Franklin Lakes, NJ, USA) in DMEM containing 10% FBS in a humidified atmosphere with 5% CO<sub>2</sub> at 37°C.

After 2 days of cultivation, the medium was changed to remove unattached cells. Glial cells were allowed to form a confluent monolayer for 7-9 days and harvested from the flask by treatment with 0.125% trypsin. Subsequently, cells were
Column effluents were monitored at 296 nm following the temperature-controlled column was maintained at 30˚C. The flow rate was 0.2 ml/min and the elution as follows: 0-5 min, 20-40% B; 5-20 min, 40-50% B; 20-21 min, 50-95% B; 21-26 min, held at 95% B; 26-33 min, 95-20% B. The tandem MS (MS/MS) experiments were set as a data-dependent scan. The experimental procedures complied with the Animal Ethics Committee Guidelines of Beijing Animals Science Biology Technology Co., Ltd. (Beijing, China; registration no. 170703002).

Qualitative assessment of arenobufagin and hellebrigenin in the cerebrospinal fluid of rats receiving a single oral dose of arenobufagin or hellebrigenin. As mice are too small to successfully collect clear cerebrospinal fluid without blood contamination, and there is no clear difference in the structure and function of the blood-brain barrier (BBB) in rats and mice, rats were used instead of mice for the qualitative assessment. Nine male Sprague Dawley rats (220-240 g) were purchased from Shanghai Shibei Biotechnology Co., Ltd. (Shanghai, China), and housed at 23±1˚C in a room with a constant humidity of 55±5% and a regular 12/12-h light/dark cycle for one week prior to experimentation. Throughout the experiment, the rats had free access to food and water. After an overnight fasting with water not limited, all animals were randomly divided into three groups (n=3) and administered the following treatments: Vehicle control (saline), arenobufagin (50 mg/kg) and hellebrigenin (50 mg/kg). All animals received a single oral dose of 50 mg arenobufagin/hellebrigenin or the same volume of saline/kg of body weight. At 30 min after the oral administration, cerebrospinal fluids were collected according to the method previously described with slight modifications (30). Briefly, the fur on the head and neck regions of rats were carefully removed, and animals were placed in an induction chamber and anesthetized. Following disinfection with ethanol, an ~2-cm skin incision was made along the midline. The spinous process and lamina were clamped with hemostatic forceps in order to make the arachnoid membrane more visible. Then, the cerebrospinal fluid was carefully extracted from the subarachnoid space using a 1-ml syringe with a 23G needle without blood contamination. Following centrifugation at 9,730 x g for 15 min at 4˚C, the cerebrospinal fluid supernatants were collected and stored at -20˚C for later analysis.

The analysis of cerebrospinal fluids was performed using the ultimate 3000 hyperbaric LC system coupled with a Velos Pro LITQ Orbitrap Mass Spectrometer via an ESI interface from Thermo Fisher Scientific, Inc. Eclipse XDB-C18 (4.6x150 mm, 3.5 µm; Agilent Technologies, Inc., Santa Clara, CA, USA) was used as the separation column in the ultra HPLC. The mobile phase consisted of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B), with the gradient elution as follows: 0-5 min, 20-40% B; 5-20 min, 40-50% B; 20-21 min, 50-95% B; 21-26 min, held at 95% B; 26-33 min, balanced to 20% B. The flow rate was 0.2 ml/min and the temperature-controlled column was maintained at 30˚C. Column effluents were monitored at 296 nm following the injection of 4 µl cerebrospinal fluid obtained from the control and treatment groups. MS detection was performed in the positive ion mode. The ESI source parameters were as follows: Ion spray voltage, +5.0 kV; sheath gas flow rate, 40 arb; aux gas flow rate, 10 arb; capillary temperature, 350˚C; and S-lens RF level, 60%. The mass resolution of Fourier transform was 30,000 with a full scan in the range of m/z 200-800. Cell viability, morphological alterations and clonogenic survival. Following treatment with various concentrations (10, 20, 30, 40, 100 and 150 ng/ml) of arenobufagin and hellebrigenin for 48 h, cell viability was measured using the XTT assay as described previously (31). Relative cell viability was expressed as the ratio of the absorbance at 450 nm of each treatment group against those of the corresponding untreated control group. The IC<sub>50</sub> values of each drug were calculated using GraphPad Prism® 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA). With respect to the morphological alterations of U-87 cells, the cells were imaged using an inverted microscope (CKX53; Olympus Corporation, Tokyo, Japan) fitted with a digital camera following treatment with various concentrations (20, 40, 100, 150 and 200 ng/ml) of arenobufagin and hellebrigenin for 48 h. Untreated cells were used as the control. Clonogenic survival assays were performed according to a method previously described, with slight modifications (14). Briefly, U-87 cells were seeded at a density of 5x10<sup>3</sup> cells/well in 6-well plates, and treated with various concentrations (5, 10, 20, 30 and 40 ng/ml) of arenobufagin and hellebrigenin for 24 h. Untreated cells were used as the control. The medium was then replaced with fresh DMEM (supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin) and the cells were allowed to grow for 7-10 days in a humidified 5% CO<sub>2</sub> atmosphere at 37˚C. Following washing gently with PBS twice, the cells were fixed with 0.25% glutaraldehyde/PBS for 15 min prior to staining with 0.2% crystal violet/PBS for 10 min at room temperature. Following a washout of extra crystal violet with water to get an adequate staining pattern, the images of crystal violet-stained cells were scanned into a computer, followed by dissolution of the violet-stained cells in 1% SDS. The absorbance of cell lysates was determined at 550 nm. The relative colony formation rate was expressed as the ratio of the absorbance at 550 nm of each treatment group against those of the corresponding untreated control group.

Cell cycle analysis. Following treatment with various concentrations (10, 20, 30 and 40 ng/ml) of arenobufagin or hellebrigenin for 48 h, and 20ng/mlarenobufaginorhellebrigenin for 24, 48 or 72 h, cell cycle analysis was performed using a FACSCanto™ flow cytometer (BD Biosciences), according to a previous method (14,21). Briefly, cells were washed twice with cold PBS, fixed with 1% paraformaldehyde/PBS on ice for 30 min, washed twice again with cold PBS, permeabilized in 70% (v/v) cold ethanol at -20˚C for at least 4 h. Cell pellets were then washed twice with cold PBS following centrifugation
(430 x g for 5 min at 4°C) and incubated with 0.25% Triton X-100 for 5 min on ice. Following centrifugation (430 x g for 5 min at 4°C) and washing with PBS, cells were resuspended in 500 µl PI/RNase A/PBS (5 µg/ml PI and 0.1% RNase A in PBS) and incubated for 30 min in the dark at room temperature. A total of 10,000 events were recorded, and FACSDiva™ software (v6.0; BD Biosciences) and ModFit LT™ v3.0 (Verity Software House, Inc., Topsham, ME, USA) were used to calculate the number of cells in each G₀/G₁, S and G2/M phase fraction.

Western blot analysis. For preparation of the protein samples, cell pellets (1-2x10⁶ per 110 µl buffer) were suspended in Laemmli buffer containing 100 mM DTT, 2 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin, 1 mM PMSF. Cell suspensions were sonicated (Qsonica, LLC, Newtown, CT, USA) with 10 short bursts of 2 sec followed by intervals of 2 sec for cooling. The suspensions were then kept in an ice bath. Sonicated cells were heated in 95°C for 5 min, and then centrifuged at 13,000 x g for 15 min at 4°C. Protein concentrations of the supernatant were determined according to Bradford's method using the Protein Assay Dye Reagent Concentrate (Bio-Rad Laboratories, Inc.), according to the manufacturer's instructions, using BSA as the standard. Western blot analysis was carried out according to methods previously described (31). Briefly, after separation of proteins (10-20 µg protein/lane) via SDS-PAGE (8, 10 or 12.5% according to the molecular weight of the target protein), followed by transfer to a polyvinylidene difluoride (PVDF) membrane, which was then blocked with 5% skim milk/PBST (PBS containing 0.5% Tween-20) for 1 h at room temperature. Protein bands were detected using the following primary antibodies: Mouse anti-human β-actin (1:5,000 dilution; cat. no. A-5441; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), rabbit anti-human Cdc25c (1:1,000 dilution; cat. no. 4688), rabbit anti-human p27 (1:1,000 dilution; cat. no. 2552), mouse anti-human Cyclin B1 (1:2,000 dilution; cat. no. 4135), mouse anti-human survivin (1:1,000 dilution; cat. no. 2802), rabbit anti-human phospho-Akt (Ser473) (1:2,000 dilution; cat. no. 9211) and Akt (1:1,000 dilution; cat. no. 4691), rabbit anti-human phospho-p38 (Thr180/Tyr182) (1:2,000 dilution; cat. no. 3838) and p38 (1:1,000 dilution; cat. no. 9212), rabbit anti-human phospho-MK2 (Thr183) (1:1,000 dilution; cat. no. 3041), rabbit anti-human phospho-ERK2 (Thr202/Tyr204) (1:2,000 dilution; cat. no. 4370) and ERK (1:1,000 dilution; cat. no. 4695; all from Cell Signaling Technology, Inc., Danvers, MA, USA). PVDF membranes containing blotted protein bands were incubated overnight with the respective horseradish peroxidase-conjugated secondary antibody (anti-mouse IgG, 1:3,000 dilution, cat. no. A9096; anti-rabbit IgG, 1:3,000 dilution, cat. no. A0545; both from Sigma-Aldrich; Merck KGaA) for 1 h at room temperature, and then detected with an enhanced chemiluminescence (ECL) analysis system (Amersham; GE Healthcare Life Sciences, Chalfont, UK).

Lactate dehydrogenase (LDH) assay. Following treatment with various concentrations (10, 20, 40, 100, 150 and 200 ng/ml) of arenobufagin or hellebrigenin for 48 h as described in the previous section of the cell viability assay, LDH leakage from U-87 cells was measured using a LDH cytotoxicity detection kit (Wako Pure Chemical Industries, Ltd.) according to the method previously described with slight modifications (31). Briefly, culture medium served as the negative control (NC). Culture supernatants (S) were collected by centrifugation at 450 x g for 5 min at 4°C and stored at -80°C until use. Cultured cells without treatment were lysed in the culture medium containing 0.2% Tween-20, and the cell lysate was used as the non-damaged positive control (PC) following centrifugation at 12,000 x g for 5 min at 4°C. In order to avoid the influence of Tween-20, culture medium containing 0.2% Tween-20 served as the negative control for PC and was referred to as NCT. Samples were diluted 16-fold with PBS and 50 µl of the diluted solution was transferred into wells of a 96-well plate. LDH activities were determined by adding 50 µl reaction reagent from the kit, followed by incubation at room temperature for 30 min. The reaction was stopped by the addition of 100 µl stopping solution provided with the kit at room temperature, and the absorbance at 560 nm was measured with a microplate reader (EMax® Plus; Molecular Devices, LLC, Sunnyvale, CA, USA). Cell damage was calculated as a percentage of LDH leakage from damaged cells using the following formula: (S-NC)/(PC-NCT) x 100.

DNA fragmentation analysis. DNA fragmentation analysis was performed according to a method described previously (32). Briefly, between 5x10⁶ and 1x10⁷ cells were used for the DNA preparation. The cells were suspended in 500 µl lysis buffer (50 mM Tris-HCl, pH 7.8, 10 mM EDTA-2Na, 0.5% sodium-N-lauroyl sarcosinate). The suspension was incubated in an ice bath for 30 min following the addition of 50 µl of 10% SDS with gentle agitation every 5 min. The lysates were incubated successively at 50°C for 90 min with protease K (1 mg/ml), at 50°C for 30 min with RNase A (1 mg/ml) and at 60°C for 15 min following the addition of the same volume of NaI solution [6.0 M NaI in 26 mM Tris-HCl, pH 8.0, 13 mM EDTA-2Na, 10 mg/ml of bovine glycogen (Nacalai Tesque, Inc., Kyoto, Japan)]. DNA was precipitated by addition of an equal volume of 100% isopropanol. DNA pellets were successively washed with 50% isopropanol, 100% isopropanol and 70% ethanol. Extracted DNA was dissolved in TE buffer (10 mM Tris-HCl, pH 7.8, 1 mM EDTA), and the DNA concentrations were determined by staining with Hoechst 33258 as described (33). The DNA samples (~20 µg DNA in 20 µl TE buffer) and 100 bp DNA ladder (Invitrogen; Thermo Fisher Scientific, Inc.) as a DNA size marker were electrophoresed on a 2% agarose X gel using TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA). Gels were visualized using 0.5 µg/ml ethidium bromide staining (at room temperature, 30 min), followed by viewing under a Luminograph II chemiluminescent imaging system (ATTO Corporation, Tokyo, Japan).

Statistical analysis. Experiments were independently repeated three times, and the results are presented as the means ± standard deviation of three assays. Statistical analysis was performed using GraphPad Prism™ 6 software. The Student's t-test was used to compare sample means between two groups, and one-way analysis of variance followed by Dunnett's post hoc test was used to compare sample means among three or more groups. P<0.05 was considered to indicate a statistically significant difference.
Results

Presence of arenobufagin, but not hellebrigenin, in cerebrospinal fluid of rats. First, whether the two active bufadienolides were able to cross the BBB was investigated. The [M+H]+ ion of arenobufagin at m/z 417.2264 (C24H33O6, Cal.417.2272, error -1.88 ppm) with a retention time of 8.97 min was only detected in the cerebrospinal fluid of rats who received a single oral dose of arenobufagin, instead of saline (vehicle control) (Fig. 1A). However, the [M+H]+ ion of hellebrigenin at m/z 417.2277 (C24H33O6, Cal.417.2272, error 1.26 ppm) with a retention time of 8.91 min was hardly detected in the cerebrospinal fluid of rats who received a single oral dose of hellebrigenin due to its very low signal intensity. The further identification of arenobufagin in cerebrospinal fluids was performed using MS/MS experiments (Fig. 1B). These results indicated that arenobufagin, but not hellebrigenin, were able to cross the BBB.

Cytotoxic effects of arenobufagin and hellebrigenin in human glioblastoma cell line U-87. A significant decrease in cell viability was observed in a dose-dependent manner in U-87 cells following treatment with various concentrations of arenobufagin and hellebrigenin for 48 h. The IC50 values of arenobufagin and hellebrigenin were 24.9±2.8 ng/ml and 23.5±2.4 ng/ml,
respectively (Fig. 2A and B). In comparison, under the same treatment conditions, no cytotoxic effect was observed in mouse primary astrocytes when treated with arenobufagin (Fig. 2C), and a slight increase in viability was observed following treatment with hellebrigenin at concentrations >10 ng/ml (Fig. 2D). Morphological alterations of U-87 cells were also observed using an inverted microscope. As shown in Fig. 2E and F, treatment with arenobufagin and hellebrigenin at concentrations >100 ng/ml for 48 h, caused a large number of U-87 cells to detach from the plate. In contrast, concentrations <40 ng/ml of each drug exhibited little effect on cell morphology, although an evident decrease in the number of cells/field was observed.
indicating an inhibition of cell viability. In comparison, almost no morphological alterations were observed in the primary astrocytes following treatment with the two bufadienolides at concentrations ≤150 ng/ml (Fig. 2G).

Inhibition of colony formation of U-87 cells by arenobufagin and hellebrigenin. To explore whether exposure to arenobufagin and hellebrigenin suppressed the surviving fraction of U-87 cells, a colony formation assay was performed. As shown in Fig. 3, significant suppression of the colony numbers of U-87 was observed following long-term treatment with arenobufagin or hellebrigenin, at concentrations ≥5 ng/ml, indicating their potency against the survival of the cells.

Effect of arenobufagin and hellebrigenin on the cell cycle, and the expression level of cell cycle-associated proteins in U-87 cells. To explore whether cell cycle arrest is involved in the cytotoxic effects of arenobufagin and hellebrigenin, cell cycle analyses were performed using flow cytometry (Figs. 4 and 5). In comparison with control group (untreated cells), a significant increase in the number of cells in the G2/M phase was observed (Figs. 4A and C, and 5A and C) following treatment with various concentrations of the two drugs for 48 h. Concomitantly, a significant decrease in the number of cells in the G0/G1 and S phase was also observed (Figs. 4A and C, and 5A and C). Furthermore, following treatment with arenobufagin or hellebrigenin at 20 ng/ml, which was almost equal to their IC50 values, for 24, 48 and 72 h, G2/M cell cycle arrest-inducing activity of each drug was observed at 24-h post-treatment, which reached the maximum at 48-h post-treatment, and was sustained for up to 72 h (Figs. 4B and D, and 5B and D). A significant decrease in the number of cells in the G0/G1 and S phase was also concomitantly observed (Figs. 4B and D, and 5B and D). As shown in Fig. 6, compared with the control group, the expression of Cdc25C and Cyclin B1 was remarkably downregulated following treatment with arenobufagin or hellebrigenin in a dose-dependent manner, although almost no evident alteration was observed in the expression levels of p27. Similarly, a dose-dependent downregulation in the expression of survivin was also observed.

Effect of arenobufagin or hellebrigenin on LDH release from U-87 cells. The release of LDH provides an accurate measure of the cell membrane integrity and cell viability (13,14,31). Following treatment with various concentrations of arenobufagin and hellebrigenin for 48 h, LDH leakage analysis was performed to examine whether the treatments affected cell membrane integrity. A dose-dependent increase in LDH leakage was observed in U-87 cells treated with arenobufagin or hellebrigenin (Fig. 7). Notably, no significant difference was observed between cells treated with each drug at 20 ng/ml and their respective control group (0 ng/ml), indicating that cell membrane damage was more likely due to relatively high concentrations, but not relatively low concentrations, of each drug.

Effect of arenobufagin or hellebrigenin on DNA fragmentation in U-87 cells. To explore whether apoptosis is involved in the cytotoxic effects of arenobufagin and hellebrigenin,
DNA fragmentation analysis was performed using DNA gel electrophoresis. As shown in Fig. 8, no DNA fragmentation was observed in U-87 cells when treated with arenobufagin or hellebrigenin, even at the concentrations >100 ng/ml, which significantly induced a large number of U-87 cells to lose their adhesive properties (Fig. 2E and F) and LDH release (Fig. 7). These results indicated that apoptosis induction was less likely to contribute to the cytotoxicity caused by arenobufagin or hellebrigenin regardless of the drug concentration. These results were also supported by the cell cycle analysis, demonstrating almost no accumulation of cells in the sub-G1 phase, which typically represents apoptotic cells (Figs. 4 and 5).

**Effect of arenobufagin or hellebrigenin on the activation of the PI3K/Akt and MAPK signaling pathway in U-87 cells.** To explore whether the PI3K/Akt and/or MAPK signaling pathway are involved in the cytoidal effects of arenobufagin and hellebrigenin, the activation of Akt, p38, Erk and JNK was determined in U-87 cells following treatment with various concentrations of arenobufagin and hellebrigenin for 48 h. As shown in Fig. 9, a substantial increase in the expression levels of phospho-p38 MAPK over the endogenous levels was detected in the cells when treated with arenobufagin or hellebrigenin, although almost no alterations in the expression levels of total p38 MAPK expression was observed. Furthermore, similar phenomena were observed in the expression levels of phospho-MAPKAPK2 (MK2), a direct downstream target of p38 MAPK. In contrast, the expression level of phospho-Akt was slightly increased along with a modest decrease in the total Akt expression. Similarly, a modest increase in the expression level of phospho-Erk and total Erk was also observed in the cells, although the highest concentrations of hellebrigenin (40 ng/ml) slightly downregulated the expression of phospho-Erk. These results indicated that the activation of
p38 MAPK was involved in the cytotoxic effects of arenobufagin and hellebrigenin, although the partial participation of Akt and Erk may not be completely excluded. In addition, the expression level of phospho-JNK was not detected regardless of the presence or absence of each drug, indicating that there was no association between JNK and the cytotoxic effects of the two drugs.

Enhancement of cytotoxicity of arenobufagin and hellebrigenin by a specific inhibitor of p38 MAPK in U-87 cells. To provide further confirm the direct involvement of p38 MAPK in the cytotoxic effects of arenobufagin and hellebrigenin, alterations to cell viability were determined in U-87 cells following treatment for 48 h with 20 ng/ml arenobufagin or hellebrigenin in the presence or absence of various concentrations of SB203580, a specific inhibitor of p38 MAPK. Consistent with the IC_{50} values of each drug (Fig. 2), treatment with 20 ng/ml of arenobufagin or hellebrigenin alone significantly reduced cell viability by ~50% (Fig. 10A-C). Compared with the groups treated with arenobufagin or hellebrigenin alone, combining various concentrations of SB203580 (1, 5 and 10 µM) with each drug significantly enhanced the cytotoxicities of the two drugs (Fig. 10A-C). Although significant reductions in the viability following treatment with each drug in combination with SB202474, a negative control for SB203580, were also observed compared with single drug treatment, the efficacy of each drug was increased more by the addition of SB203580 in comparison with SB202474, indicating the critical role of p38 MAPK. Notably, a dose-dependent decease in the cell viability was observed in cells treated with various concentrations of SB203580 (1, 5 and 10 µM) alone, but not SB202474 alone. In order to evaluate whether there was an association between the activation of the p38 MAPK pathway and other cellular responses, alterations to cell cycle arrest, LDH

Figure 5. Effect of Helle on the cell cycle profiling in U-87 cells. Following treatment with various concentrations of Helle (10, 20, 30 and 40 ng/ml) for 48 h (A), or 20 ng/ml Helle for 24, 48 and 72 h (B), cell cycle analysis was performed using a FACSCount flow cytometer as described in Materials and methods. ModFit LT™ v3.0 was then used to calculate the number of cells in each G_{0}/G_{1}, S and G_{2}/M phase fraction following treatment (C) with the indicated concentrations of Helle for 48 h, or (D) with 20 ng/ml Helle for the indicated time periods (D). A representative FACS histogram from three independent experiments is shown. Data are presented as the mean ± standard deviation from three independent experiments. †P<0.01, ‡P<0.001 and ††P<0.0001 vs. respective control. Helle, hellebrigenin.
leakage and DNA fragmentation were further determined in cells. No alteration in LDH leakage (Fig. 10D), G2/M cell cycle arrest (Fig. 11) or DNA fragmentation (Fig. 8B and C) was observed in the cells treated with a combination of each drug and SB203580 when compared with treatment with each drug alone, indicating no association between the activation of p38 MAPK signaling pathway and these cellular responses.

Discussion

Due to the restrictive nature of the BBB, the delivery of anticancer drugs to the central nervous system remains a major challenge to the treatment of glioblastoma. Much effort has been directed towards developing a novel system such as nanoparticulate formulation for brain delivery of drugs (34,35). In the present study, the qualitative assessment demonstrated for the first time the existence of arenobufagin, but not hellebrigenin, in the cerebrospinal fluid of rats who received a single oral dose of the drug, directly indicating the capacity of arenobufagin to cross the BBB. In fact, previous biodistribution studies have demonstrated that other active bufadienolide compounds with similar structures to arenobufagin, including bufotalin, bufalin, resibufogenin and cinobufagin, were primarily distributed in the brain, lung and spleen (35,36), and the longest retention was observed in the brain (35), as a result of the intravenous delivery of these compounds to mice. Compared with the chemical structure of arenobufagin, hellebrigenin contains a formyl group instead of a methyl group at position 19 of the molecule. Thus, it was suggested that the difference in their chemical structure may be associated with the differing ability to cross the BBB, although further investigation is required to confirm this. Collectively, these results indicate the possibility of the clinical application of arenobufagin for patients with glioblastoma. However, quantitative evaluation of arenobufagin levels in cerebrospinal fluid is required to clarify whether its exact concentration is adequate to achieve the inhibition of brain cancer cell viability.

It was further demonstrated that arenobufagin and hellebrigenin exhibited similar dose-dependent cytotoxic effects against U-87 cells as evidenced by the XTT assay, as well as morphological alterations and colony formation inhibitory properties. In comparison, the same treatments did not cause any detectable toxic effects in mouse primary astrocytes, and the addition of hellebrigenin even resulted in enhanced viability of the cells, although we are unable to provide a plausible explanation for the phenomena at present. Similarly, it was previously demonstrated that arenobufagin possesses selective cytotoxic activity against human tumor cells, including U-87 and a pancreatic cancer cell line SW1990 rather than PBMCs (9). These results provide further evidence for the efficacy of arenobufagin and hellebrigenin against cancerous glial cells with high potency, selectivity and tolerability, although elucidation of their physiological mechanisms underlying differential responses between tumor and normal cells is required. In addition, Meng et al. (8) demonstrated that cinobufacin possesses effective anticancer activity in patients with hepatocellular carcinoma and pancreatic cancer with low toxicity and few side effects. Collectively, these findings provide a rationale for the clinical application of arenobufagin and/or hellebrigenin for patients with glioblastoma.

Active bufadienolide compounds, including bufalin, arenobufagin and hellebrigenin, have been demonstrated to induce G2/M cell cycle arrest in human hepatocellular...
In line with these previous findings, treatment with arenobufagin or hellebrigenin caused dose- and time-dependent accumulation of cells in the G2/M phase, along with a significant decrease in the number in G0/G1 and S phase cells. Concomitantly, a remarkable downregulation of the expression levels of Cdc25C and Cyclin B1, key regulators involved in the G2/M cell cycle transition (37,38), was further observed in the treated cells compared with the control (untreated cells). A number of previous studies have demonstrated that in glioblastoma cell lines, downregulation of the expression levels of Cdc25C and Cyclin B1 has been implicated in the G2/M phase arrest induced by various antitumor agents, including arsenic trioxide (39), tivozanib, a pan-inhibitor of vascular endothelial growth factor (40), and knockdown of β-arrestin 1, a mediator of tachykinin receptor neurokinin-1 signaling pathway responsible for cell proliferation (41). Survivin, an important cancer-associated protein, is highly expressed in the majority of human tumor cells, including primary human glioblastoma cells (19), and its inhibition has been considered as a compelling strategy for cancer therapy (42). It has been demonstrated that nuclear survivin expression may be a useful biomarker for predicting the prognosis in patients with glioblastoma (43). Furthermore, suppression of survivin by small interfering RNA results in reduced proliferation and G2/M cell cycle arrest in human cancer cells, including HeLa, a human cervical cancer cell line, and MCF-7, a human breast cancer cell line (44). In the present study, similar to Cdc25C and Cyclin B1, a dose-dependent downregulation of survivin expression was observed, suggesting survivin serves an important role in the G2/M phase arrest induced by arenobufagin and hellebrigenin.
It was further demonstrated that necrotic cell death was observed in U-87 cells when treated with a relatively high concentration (>100 ng/ml), but not a relatively low concentration (<40 ng/ml) of each drug as evidenced by the LDH leakage assay. However, apoptotic DNA fragmentation was not observed in the cells regardless of drug concentrations used, although arenobufagin and hellebrigenin have been reported to induce apoptosis in human hepatocellular carcinoma cells (16,45), suggesting whether induction of apoptosis by arenobufagin or hellebrigenin may be cell-specific. Collectively, rather than apoptosis induction, cell cycle arrest and necrotic cell death are more likely to contribute the cytotoxicity induced by a relatively low and high concentration of each drug.

Increasing evidence has indicated an important role for the PI3K/Akt signaling pathway in the regulation of cell survival and death in response to diverse stimuli, including the majority...
of chemotherapeutic agents (46,47). In addition, members of the MAPK family, consisting of p38, Erk and JNK, are also involved in a range of cellular functions, including proliferation, cell cycle arrest and cell death (26,27,48,49). In the present study, evident activation of p38 MAPK pathway was observed in U-87 cells when treated with arenobufagin or hellebrigenin as evidenced by a marked increase in the expression levels of phospho-p38 and its direct downstream target, phospho-MK2 (25). In comparison to the expression pattern of phospho-p38, only a modest increase in the expression level of phospho-Akt and phospho-Erk was observed in the treated cells, and no expression of phospho-JNK was detected regardless of treatment with the two drugs. These results thus suggest that the cytotoxicities of arenobufagin and hellebrigenin are primarily associated with p38 MAPK, rather than Akt, Erk and JNK, and led to the exploration of the possible functional interactions between the activation of the p38 MAPK pathway and the cytotoxicities of the two drugs. It was surprising that a specific inhibitor of p38 MAPK per se caused a significant decrease in the cell viability, and enhanced the cytotoxicity of arenobufagin or hellebrigenin as evidenced by the XTT assays, suggesting that p38 MAPK serves an important pro-survival role in the cells. In agreement with these findings, previous studies have demonstrated a pro-survival role for p38 MAPK in different types of cells, including human glioblastoma cells (48,50). Sooman et al (27) reported that p38 MAPK phosphorylation may be a prognostic marker for patients with high-grade glioma, and vandetanib combined with a p38 MAPK inhibitor may be a useful combination chemotherapy for patients with glioma. Considering the results of previous studies and the observations in the present study, we hypothesized that combining a p38 MAPK inhibitor with arenobufagin or hellebrigenin may improve the efficacy of both drugs, and may provide more therapeutic benefits to patients with glioblastoma, although the precise contribution of the p38 MAPK pathway to the cytotoxicity of the two drugs warrants further investigation in a glioblastoma xenograft model. Although the activation of p38 MAPK has been associated with cell cycle arrest, apoptotic and necrotic cell death in other cancer cells, including HL-60, a human promyelocytic cell line and MCF-7 (21,26), no alteration in G$_2$/M cell cycle arrest as well as necrotic cell death were attributed to their toxicities. Considering the important role of survivin in diverse cellular responses in various types of cancer cells, including glioblastoma (19,42,43), the cytotoxicity of both drugs against cancer cells may be primarily attributed to the downregulation of survivin expression. The efforts to evaluate the mechanisms underlying functional interactions between survivin and cellular responses, including cell cycle arrest and necrotic cell death, in the treated U-87 cells in our laboratory are ongoing. Given that p38 MAPK serves an essential role in promoting glioblastoma cell survival (27,50), and as an optimal chemotherapeutic regimen for glioblastoma has not been defined at present (53,54), developing a combination regimen of arenobufagin/hellebrigenin plus a p38 MAPK inhibitor with the aim of preventing the activation of the p38 MAPK pathway may provide novel insight into approaches designed to treat glioblastoma. To the best of our knowledge, the results of the present study demonstrated, for the first time, the existence of arenobufagin in cerebrospinal fluid of rats who received a single oral dose of the drug, supporting the clinical application of arenobufagin and/or hellebrigenin for patients with glioblastoma.

Acknowledgements
Not applicable.

Funding
This study was supported in part by grants from the National Standardization Project of Chinese Medicine (grant no. ZYBZH-C-AH-01).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
LH and BY contributed equally to this study; LH, RS and BY performed experiments; BY and LH analyzed results and
presented; HH, NS, HZ, BB and NT assisted interpretation of the result with BY; BY designed the research and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The experimental procedures complied with the Animal Ethics Committee Guidelines of Beijing Animals Science Biotechnology Co., Ltd. (Beijing, China; registration no. 170703002) and was approved by the Committee of Animal Care and Welfare of Tokyo University of Pharmacy and Life Sciences (Tokyo, Japan; registration no. P17-60).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Furnari FB, Benten T, Bachoo RM, Mukasa A, Stommel JM, Siegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al: Malignant astrocytic glioma: Genetics, biology, and path to treatment. Genes Dev 21: 2683-2710, 2007.
2. Stupp R, Tonn JC, Brada M and Pentheroudakis G; ESMO Guidelines Working Group: High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 1): v1-v18, 2010.
3. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburg JJ and Rich NH: Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24, 2007.
4. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
6. Chen Z, Zhai XF, Su YH, Wan YX, Li J, Xie JM and Gao B: Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer. Zhong Xi Yi Jie He Xue Bao 1: 184-186, 2003 (In Chinese).
7. Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined with docetaxel in patients with advanced gallbladder carcinoma. World J Gastroenterol 14: 5210-5216, 2008.
8. Meng Z, Yang F, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, et al; Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 115: 5309-5318, 2009.
9. Yuan B, He J, Kisoh K, Hayashi H, Tanaka S, Ni Z, Zhao HY, Hirano T, Bian B and Takagi N: Effects of effective bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. Oncol Rep 36: 1377-1384, 2016.
10. Facciuabene A, Motz GT and Coukos G: T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res 72: 2162-2172, 2012.
11. Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, Izawa S and Fujii H: Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101: 1947-1954, 2010.
12. Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005.
13. Kon A, Yuan B, Hanazawa T, Kikuchi H, Sato M, Furutani R, Takagi N and Toyoda H: Contribution of membrane progesterone receptor a to the induction of progesterone-mediated apoptosis associated with mitochondrial membrane disruption and caspase caspase-3 activation in Jurkat cell lines. Oncol Rep 30: 1965-1970, 2013.
14. Yao M, Yuan B, Wang X, Sato A, Sakuma K, Kaneko K, Komuro H, Okazaki A, Hayashi H, Toyoda H, et al: Synergistic cytotoxic effects of arsenite and tetradrimer in human breast cancer cell line MCF-7. Int J Oncol 51: 587-598, 2017.
15. Yuan B, Okusumi S, Yoshino Y, Moriyama C, Tanaka S, Hirano T, Takagi N and Toyoda H: Delphinidin induces cytotoxicity and potentiates cytotoxic effect in combination with arsenite in an acute promyelocytic leukemia NB4 cell line. Oncol Rep 37: 1417-1426, 2015.
16. Deng LJ, Hu LP, Peng QL, Yang XL, Bai LL, Yiu A, Li Y, Tian HY, Ye WC and Zhang DM: Hellebrigenin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells through inhibition of Akt. Chem Biol Interact 219: 184-194, 2014.
17. Deng LJ, Peng QL, Wang LH, Xu J, Liu JS, Li YJ, Zhuo ZJ, Bai LL, Hu LP, Chen WM, et al: Areobufuginiferol intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR pathway. Oncotarget 6: 34258-34275, 2015.
18. Hsu CM, Tsai Y, Wan L and Tsai FJ: Bufalin induces G2/M phase arrest and triggers autophagy via the TNF-JNK, BECN-1 and ATG8 pathway in human hepatoma HepG2 cells. Int J Oncol 43: 338-347, 2013.
19. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nesterl U, Song Q and Loeffer J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23: 7494-7506, 2004.
20. Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol Mol Biol Rev 75: 50-83, 2011.
21. Kikuchi H, Yuan B, Yuhara E, Takagi N and Toyoda H: Involvement of histone H3 phosphorylation through p38 MAPK pathway activation in casticin-induced cytotoxic effects against the human promyelocytic cell line HL-60. Int J Oncol 43: 2046-2056, 2013.
22. Yao J, Qian CJ, Ye B, Zhang X and Liang Y: ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-kB-dependent and Notch-independent mechanism. Life Sci 91: 186-193, 2012.
23. Kikuchi H, Yuan B, Yuhara E, Imairi M, Furutani R, Fukushima S, Hazama S, Hirobe C, Ohyama K, Takagi N, et al: Involvement of histone h3 phosphorylation via the activation of p38 MAPK pathway and intracellular redox status in cytotoxicity of HL-60 cells induced by Vitex agnus-castus fruit extract. Int J Oncol 45: 843-852, 2014.
24. Zanotto-Filho A, Braganhol E, Battistini AM and Moreira JC: Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of the G(2) DNA damage checkpoint in human cancer cells. Mol Cancer 5: 1759-1774, 2013.
25. Phong MS, Van Horn RD, Li S, Tucker-Kellogg G, Surana U and Ye XS: p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells. Mol Cell 30: 3816-3826, 2010.
26. Pereira L, Igea A, Canovas B, Doloado I and Nebreda AR: Inhibition of p38 MAPK sensitizes tumor cells to cisplatin-induced apoptosis meditated by reactive oxygen species and JNK. EMBO Mol Med 6: 1579-1774, 2013.
27. Sooman L, Lenearsson J, Gullbo J, Bergqvist M, Tsson G, Lennartsson J, Gullbo J, Bergqvist M, Tsakonas G, Sooman L, Lennartsson J, Gullbo J, Bergqvist M, Tsakonas G, et al: Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival. Med Oncol 30: 638, 2013.
28. Van Heerden FR and Vleggaar R: A revised 13C NMR spectral guidelines Working Group: High-grade malignant glioma: Report of the Cancer Imaging of glioblastoma cells by 13C NMR spectroscopy. Cancer Imaging 1: 7494-7506, 2004.
29. Hayashi H, Campenot RB, Vance DE and Vance JE: Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J Biol Chem 279: 14009-14015, 2004.
30. Cao YD, Zhang LZ, Wang MS, Tang TY and Su WH: Two methods to collect cerebrospinal fluid in SD rat. Acta Acad Sinica 31: 217-221, 2002.
31. Kroetz DL and Toyoda H: Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol 257: 198-208, 2011.
32. Yuan B, Ohyama K, Bessho T, Uchide N and Toyoda H: Imbalance between ROS production and elimination results in apoptosis induction in primary smooth chorion trophoblast cells prepared from human fetal membrane tissues. Life Sci 82: 623-630, 2008.

33. Cesarone CF, Bolognesi C and Santi L: Improved micromolitometric DNA determination in biological material using 33258 Hoechst. Anal Biochem 100: 188-197, 1979.

34. Kreuter J: Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47: 65-81, 2001.

35. Li F, Weng Y, Wang L, He H, Yang J and Tang X: The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm 393: 203-211, 2010.

36. Yu CL and Hou HM: Plasma pharmacokinetics and tissue distribution of bufotalin in mice following single-bolus injection and constant-rate infusion of bufotalin solution. Eur J Drug Metab Pharmacokinet 35: 115-121, 2011.

37. Gavet O and Pines J: Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell 18: 533-543, 2010.

38. Perdiguer E and Nebreda AR: Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle 3: 733-737, 2004.

39. Zhao S, Tsuchida T, Kawakami K, Shi C and Kawamoto K: Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 21: 49-55, 2002.

40. Momeny M, Moghaddaskho F, Gortany NK, Yousefi H, Sabourinejad Z, Zarrinrad G, Mirshahvaladi S, Eyvani H, Barghi F, Ahmadinia L, et al: Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Sci Rep 7: 44075, 2017.

41. Zhang YX, Li XF, Yuan GQ, Hu H, Song XY, Li JY, Miao XK, Zhou TX, Yang WL, Zhang XW, et al: β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition. J Biol Chem 292: 8933-8947, 2017.

42. Chen X, Duan N, Zhang C and Zhang W: Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer 7: 314-323, 2016.

43. Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Suzuki Y, Itoh J, Itoh H, Ishiuchi S, Sakurai H, et al: Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 91: 353-358, 2009.

44. Li Y, Liu D, Zhou Y, Li Y, Xie J, Lee RJ, Cai Y and Teng L: Silencing of survivin expression leads to reduced proliferation and cell cycle arrest in cancer cells. J Cancer 6: 1187-1194, 2015.

45. Zhang DM, Liu JS, Deng L, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, et al: Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis 34: 1331-1342, 2013.

46. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.

47. Garcia-Echeverria C and Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-5526, 2008.

48. Gutierrez-Uzquiza Á, Arechederra M, Bragado P, Aguirre-Ghiso JA and Porras A: p38α mediates cell survival in response to oxidative stress via induction of antioxidant genes: Effect on the p70S6K pathway. J Biol Chem 287: 2632-2642, 2012.

49. Chen Y, Yang W, Zhang X, Yang S, Peng G, Wu T, Zhou Y, Huang C, Reinch PS, Li W, et al: MK2 inhibitor reduces alkali burn-induced inflammation in rat cornea. Sci Rep 6: 28145, 2016.

50. Yoshino Y, Aoyagi M, Tamaki M, Duan L, Morimoto T and Ohno K: Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. Int J Oncol 29: 981-987, 2006.

51. Allen M, Bjerke M, Edlund H, Nelander S and Westermarck B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med 8: 354dc3, 2016.

52. Marampon F, Megiorni F, Camero S, Crescioli C, McDowell HP, Sferra R, Vetuschi A, Pompili S, Ventura L, De Felice F, et al: HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. Cancer Lett 397: 1-11, 2017.

53. Fine HA, Dear KB, Loeffler JS, Black PM and Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993.

54. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.